The below letter is worth reading but is too long to quote fully, so I'll retrict myself to highlighting just one passage from the conclusions:
http://users.ox.ac.uk/~sfos0060/Biggs_E ... ockers.pdfIn fact, the initial results showed predominantly negative outcomes. The only tabulated
data available, for 30 of the subjects after a year on triptorelin, showed that children reported
greater self-harm; girls experienced more behavioural and emotional problems and expressed
greater dissatisfaction with their body—so drugs exacerbated gender dysphoria (GIDS 2015).
The fact that these outcomes have never been published is a serious indictment of Carmichael,
Viner (now President of the Royal College of Paediatrics and Child Health), Di Ceglie, and
the other scientists who proposed the research.8 The failure can be highlighted by comparing
another use of triptorelin: the treatment of hypersexuality in men, for which it is licensed. The
chemical castration of seven dangerous sex offenders in Broadmoor Hospital resulted in a
report spanning two pages, which detailed the adverse side effects experienced by three
patients (Ho et al. 2012). The use of triptorelin on 44 adolescents—off license—has produced
only two single-page abstracts reporting outcomes for subsets of the subjects (Catanzano and
Butler 2018; Tobin, Ting, and Butler 2018).
